According to statistics, the incidence of rheumatoid arthritis in China is 0.2% to 0.36%, and the number of patients is up to 5 to 10 million. Like rheumatoid arthritis, osteoarthritis is one of the most common arthritis and a manifestation of articular degeneration with age. At the end of 2017, the number of people aged 60 and above reached 241 million in China, accounting for 17.3% of the total population. Some research has pointed out that over 60% of Chinese people aged 60 and above are suffering from osteoarthritis as the population is ageing. Typical symptoms of osteoarthritis are joint pains, joint deformities, and joint dysfunction, decreasing patients’ mobility and quality of life.
Ossotide can regulate bone metabolism and stimulate the proliferation of bone cells to foster the formation of new bones. It can also regulate calcium and phosphorus metabolism and increase bone calcium deposition to prevent osteoporosis. Ossotide was originally developed by Nanjing Xinbai Pharmaceutical Co., Ltd. There are many Ossotide manufacturers in China. The top 5 market players are Harbin Medisan Pharmaceutical Co., Ltd., Heilongjiang ZBD Pharmaceutical Co., Ltd., Heilongjiang Jiangshi Pharmaceutical Co., Ltd., Nanjing Xinbai Pharmaceutical Co., Ltd. and Anhui Hongye Pharmaceutical Co., Ltd. In 2017, their market share by sales revenue reached over 90%. Harbin Medisan Pharmaceutical Co., Ltd. captured the biggest market share by sales value about 35%.
According to CRI, after Ossotide was launched in China, the sales value of Ossotide kept growing before 2012 and fluctuated from 2013 to 2017. Overall, the annual sales value in China increased from less than CNY 120 million in 2007 to CNY 363 million in 2017. The Chinese Ossotide market will continue to grow in the coming years.
– Development environment of Ossotide
– Sales of Ossotide in China
– Competition pattern of Chinese Ossotide Market
– Major Ossotide manufacturers in China
– Prices of Ossotide in China
– Prospect of the Chinese Ossotide market from 2018 to 2022